论文部分内容阅读
【案情介绍】根据西藏诺迪康药业股份有限公司(以下简称“西藏药业”)2014年半年度报告显示,西藏华西药业集团有限公司(以下简称“华西药业”)持有西藏药业的股份为3 148万股,占总股本的21.62%;北京新凤凰城房地产开发有限公司(以下简称“新凤凰城”)持有西藏药业的股份为2 696万股,占总股本的18.52%,新凤凰城及一致行动人的持股比例为21.61%;西藏通盈投资有限公司(以下简称“西藏通盈”)持有西藏药业的股份为4 503 119
According to the semi-annual report 2014 of Tibet Nuodikang Pharmaceutical Co., Ltd. (hereinafter referred to as “Tibet Pharmaceutical”), Tibet Huaxi Pharmaceutical Group Co., Ltd. (hereinafter referred to as Huaxi Pharmaceutical) Tibet Pharmaceutical held 3,148,000 shares, accounting for 21.62% of the total share capital; Beijing New Phoenix Real Estate Development Co., Ltd. (hereinafter referred to as “New Phoenix”) held 29,600,000 shares in Tibet Pharmaceutical Stake, accounting for 18.52% of the total share capital of New Phoenix and acting in concert for 21.61% stake in Tibet Tong Ying Investment Co., Ltd. (hereinafter referred to as “Tibet Tongying”) shares held by Tibet Pharmaceutical 4 503 119